Antiseinse strategies in degenerative joint diseases: Sense or nonsense?

被引:13
作者
Huber, Lars C. [1 ]
Distler, Oliver [1 ]
Gay, Renate E. [1 ]
Gay, Steffen [1 ]
机构
[1] Univ Zurich, Collaborating Ctr Mol Biol & Novel Therapeut Stra, Ctr Expt Rheumatol, WHO,CIHP,Univ Hosp Zurich, CH-8091 Zurich, Switzerland
关键词
oligodeoxynucleotides; RNAi; ribozymes; drug design; cartilage destruction; osteoarthritis; rheumatoid arthritis;
D O I
10.1016/j.addr.2006.01.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oligodeoxynuleotides, ribozymes, and RNA interference make part of the antisense strategy, a new tool proposed to conquer cancer, viral infections, as well as cardiovascular and rheumatic diseases. The silencing effect of antisense strategies is both highly specific and potent - and only requires that the sequence of the target RNA is known. However, so far neither RNAi nor ribozymes have been approved for clinical use and only a single antisense agent is on the market. In the context of degenerative joint diseases, experimental data in the field of antisense strategies are still rare. Several studies from rheumatoid arthritis (RA), an inflammatory condition that leads to the progressive destruction of cartilage and bone within affected joints, however revealed promising results and taught us important lessons that might also be useful in therapeutic approaches for ostcoarthritis (OA). To introduce these therapies in clinical practice, however, several hurdles still have to be overcome. (c) 2006 Elsevier B.V All rights reserved.
引用
收藏
页码:285 / 299
页数:15
相关论文
共 82 条
[1]   Nitric oxide and inflammatory mediators in the perpetuation of osteoarthritis [J].
Abramson S.B. ;
Attur M. ;
Amin A.R. ;
Clancy R. .
Current Rheumatology Reports, 2001, 3 (6) :535-541
[2]   PRESENCE OF CATHEPSIN B IN CARTILAGE [J].
ALI, SY .
BIOCHEMICAL JOURNAL, 1967, 102 (01) :C10-&
[3]   COX-2, NO, and cartilage damage and repair. [J].
Amin A.R. ;
Dave M. ;
Attur M. ;
Abramson S.B. .
Current Rheumatology Reports, 2000, 2 (6) :447-453
[4]   Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA [J].
Anderson, KP ;
Fox, MC ;
BrownDriver, V ;
Martin, MJ ;
Azad, RF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2004-2011
[5]   Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas [J].
Andrews, DW ;
Resnicoff, M ;
Flanders, AE ;
Kenyon, L ;
Curtis, M ;
Merli, G ;
Baserga, R ;
Iliakis, G ;
Aiken, RD .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2189-2200
[6]   Molecular medicine - Antisense oligonucleotide therapy [J].
Askari, FK ;
McDonnell, WM .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :316-318
[7]   Osteoarthritis or osteoarthrosis: the definition of inflammation becomes a semantic issue in the genomic era of molecular medicine [J].
Attur, MG ;
Dave, M ;
Akamatsu, M ;
Katoh, M ;
Amin, AR .
OSTEOARTHRITIS AND CARTILAGE, 2002, 10 (01) :1-4
[8]   Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34(+) cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes [J].
Bauer, G ;
Valdez, P ;
Kearns, K ;
Bahner, I ;
Wen, SF ;
Zaia, JA ;
Kohn, DB .
BLOOD, 1997, 89 (07) :2259-2267
[9]   The AP-1 site and MMP gene regulation: What is all the fuss about? [J].
Benbow, U ;
Brinckerhoff, CE .
MATRIX BIOLOGY, 1997, 15 (8-9) :519-526
[10]   Signaling transduction: target in osteoarthritis [J].
Berenbaum, F .
CURRENT OPINION IN RHEUMATOLOGY, 2004, 16 (05) :616-622